Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Taprenepag isopropyl is a highly selective agonist of the EP2 receptor.
Description | Taprenepag isopropyl is a highly selective agonist of the EP2 receptor. |
In vivo | Intraocular pressure (IOP) in the left, vehicle-dosed eye typically remains within the normal range. In the right (Taprenepag isopropyl-dosed) eye, IOP is reduced in all dose groups. In the high-dose group, IOP is reduced to the extent that it cannot be measured (<4mm Hg) on Days 22 and 29. There are no clinical signs or changes in body weight observed with any dose of Taprenepag isopropyl administration, and no ocular findings occur for animals in the low-dose group (0.75 mg/day) [1]. |
Synonyms | PF-04217329 |
Molecular Weight | 520.6 |
Formula | C27H28N4O5S |
CAS No. | 1005549-94-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Taprenepag isopropyl 1005549-94-9 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor PF-04217329 Inhibitor inhibitor inhibit